Outcome of patients with membranous lupus nephritis in Cape Town South Africa

Nephrology Dialysis Transplantation

Volumn 27, Issue 9, 2012, Pages 3509-3515

  Okpechi, Ikechi G ^a   Ayodele, Olugbenga E ^b   Jones, Erika S W ^a   Duffield, Maureen ^a   Swanepoel, Charles R ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Ladoke Akintola University   (Nigeria)

Author keywords

Africans; blood pressure; chloroquine; membranous lupus nephritis; outcomes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLOROQUINE; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID; PREDNISONE;

ADULT; ALOPECIA; AMENORRHEA; ARTICLE; AVASCULAR NECROSIS; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CUSHINGOID SYNDROME; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; EVENT FREE SURVIVAL; FEMALE; GLOMERULUS FILTRATION; HERPES ZOSTER; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LIVER BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MENINGITIS; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; PYELONEPHRITIS; REMISSION; RETROSPECTIVE STUDY; SEPTICEMIA; SOUTH AFRICA; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; BLOOD PRESSURE; CELL MEMBRANE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SOUTH AFRICA; SURVIVAL RATE;

EID: 84865734756     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs122     Document Type: Article

References (31)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424.
2. Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 1992; 19: 473-479.
3. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
4. Grootscholten C, Ligtenberg G, Hagen EC et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70: 732-742.
5. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
6. Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology (Carlton) 2010; 15: 482-490.
7. Wang J, Hu W, Xie H et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16: 707-712.
8. Pasquali S, Banfi G, Zucchelli A et al. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993; 39: 175-182.
9. Sloan RP, Schartz MM, Korbet SM et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol 1996; 7: 299-305.
10. Radhakrishan I, Szabolcs M, D'Agati V et al. Lupus membranous nephropathy: course and prognostic in 50 patients (abstract). J Am Soc Nephrol 1993; 4: 284.
11. Mercadal L, Montcel ST, Nochy D et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002; 17: 1771-1778.
12. Sisa A, Ramos-Casals M, Bova A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008; 17: 281-288.
13. National Kidney FoundationK/DOQI clinical practice guidelines for chronic kidney disease; evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-S266.
14. Mansia G, De Backer G, Dominiczak A et al. 2007 European Society of Cardiology and European Society of Hypertension Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.
15. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-432.
16. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
17. Austin HA, III, Muenz LR, Joyce KM et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
18. Sloan RP, Schwartz MM, Korbet SM et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996; 7: 299-305.
19. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-154.
20. Fessler BJ, Alarca GS, McGwin G, Jr et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473-1480.
21. Pons-Estel GJ, Alarca GS, McGwin G, Jr et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009; 61: 830-839.
22. Kasitanon N, Fine DM, Haas M et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006; 15: 366-370.
23. Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577-583.
24. Vlad SC. Protective effect of hydroxychloroquine on renal damage may be biased: comment on the article by Pons-Estel et al. Arthritis Rheum 2009; 61: 1614.
25. Sun HO, Hu WX, Xie HL et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus 2008; 17: 56-61.
26. Okpechi IG, Swanepoel CR, Rayner BL. Outcomes of rationing dialysis therapy in biopsy-proven end-stage renal disease in South Africa. J Nephrol 2011. .
27. Cort-Hermdez J, Ordi-Ros J, Labrador M et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287-296.
28. Alarca GS, McGwin G, Jr, Petri M et al. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med 2006; 3: e396.
29. De Castro WP, Morales JV, Wagner MB et al. Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide? Lupus 2007; 16: 724-730.
30. Kitamura N, Matsukawa Y, Takei M et al. Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis. J Int Med Res 2009; 37: 892-898.
31. Chen YE, Korbet SM, Katz RS et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46-53.